Last updated: March 2026
Finasteride is the most clinically validated oral treatment for male pattern baldness. By blocking 5α-reductase type II, it cuts scalp and serum DHT by ~65%, halting progression in the majority of men and promoting visible regrowth in many.
Finasteride doesn't block testosterone — it blocks its conversion to DHT. Dihydrotestosterone (DHT) binds to androgen receptors in hair follicles with ~3x greater affinity than testosterone, miniaturizing follicles over time. By cutting DHT production at the enzyme level, finasteride preserves follicle size and hair diameter.
Finasteride competitively inhibits the 5α-reductase type II isoenzyme — the enzyme responsible for converting testosterone to DHT in the scalp, prostate, and skin. It forms a stable complex with the enzyme, reducing DHT production by ~65-70% in serum and ~64% in scalp tissue at the 1mg dose.
DHT binds androgen receptors in genetically susceptible follicles with ~3x greater potency than testosterone. This progressively shortens the anagen (growth) phase and miniaturizes follicles from terminal to vellus hairs. Finasteride interrupts this cascade by starving the follicle of its primary androgen signal.
Because finasteride blocks the DHT pathway, testosterone (the substrate) accumulates. Serum testosterone levels increase ~10-15% on finasteride 1mg. This compensatory rise is generally well-tolerated but contributes to increased aromatization to estradiol in some men — the mechanism behind rare gynecomastia.
Hair follicles cycle slowly. Clinical trials show initial effects at 3-6 months, with maximal benefit at 12-24 months. Hair count improvements are modest early but compound over years of use. Discontinuation reverses DHT suppression within weeks, and progression typically resumes within 6-12 months of stopping.
Data primarily from the pivotal 1998 NEJM trial (Merck, N=1553) and subsequent long-term extension studies. All figures for finasteride 1mg in men with mild-to-moderate androgenetic alopecia.
Incidence rates from the FDA prescribing information and pivotal clinical trials. Sexual side effects are the primary concern. Most resolve with discontinuation for the majority of users.
Post-finasteride syndrome refers to a cluster of persistent sexual dysfunction, neurological symptoms (brain fog, depression, anxiety), and endocrine disruption reported by a subset of men after stopping finasteride — sometimes weeks to months after the drug is cleared. The Post-Finasteride Syndrome Foundation has documented hundreds of such cases.
The medical community remains divided. Published case reports and patient registries support the existence of persistent symptoms in a real subset of users. However, high-quality prospective data on prevalence is lacking. The FDA added a warning to finasteride labeling in 2012 acknowledging reports of persistent sexual adverse events. Mechanistically, some researchers hypothesize neurosteroid disruption (DHT is a precursor to allopregnanolone, a GABA-A positive modulator) as a potential pathway.
Bottom line: PFS appears real for a subset of men. Its prevalence is unknown but likely low. Men with a personal or family history of depression, anxiety, or sexual dysfunction may warrant extra caution. Discuss risk vs. benefit with your physician before starting.
Scalp care tools frequently combined with finasteride therapy.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. It is not medical advice. Finasteride is a prescription medication that should only be used under the supervision of a licensed healthcare provider. It is contraindicated in women who are or may become pregnant. Always consult a qualified physician before starting any pharmaceutical therapy.